ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Lower risk of seizure recurrence with levetiracetam and oxcarbazepine after withdrawal in pediatric epilepsy: a pilot study.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is no consensus on the optimal timing for discontinuing antiseizure medications (ASMs) and the associated risk factors for seizure recurrence in children with epilepsy. This study aimed to assess the ideal timing for discontinuation, the frequency and predictors of seizure recurrence, the risk factors associated with the cessation of ASMs and the potential impact of specific ASMs on seizure recurrence in children with epilepsy.
methodsThe study included 211 children aged between one month and fifteen years who had been treated with ASMs and were followed for a minimum of two years after medication withdrawal.
resultsThe overall seizure recurrence rate was 30% with 75% of these recurrences occurring during the tapering period and within the first year after ASM withdrawal. The risk of seizure recurrence was significantly lower in patients using levetiracetam and oxcarbazepine compared to those taking valproate and carbamazepine. Specifically, the seizure recurrence rates were significantly lower in levetiracetam group than valproate (p = 0.006) and carbamazepine (p = 0.025) groups. Similarly, children taking oxcarbazepine experienced fewer seizure recurrences compared to those receiving carbamazepine (p = 0.011). In multivariate Cox regression analysis, a treatment duration less than three years was identified as the main risk factor for seizure recurrence (OR: 2.974, CI: 1.684-5.252, p value: 0.001).
conclusionThe risk of seizure recurrence was lower in patients treated with newer generation ASMs, levetiracetam and oxcarbazepine compared to those using valproate and carbamazepine. We suggest that ASMs should be continued for at least three years before considering treatment discontinuation.
Indexed as
Identifiers
40973868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.